Compare Citius Pharmaceuticals Inc (CTXR) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares Core MSCI EAFE ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while iShares Core MSCI EAFE ETF trades at $96.34 (market cap $189.19B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 13890.6× Citius Pharmaceuticals Inc's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and iShares Core MSCI EAFE ETF for 41 Days on average.
| CTXR | IEFA | |
|---|---|---|
Market Cap | $13.62M | $189.19B |
Volume | 132,438 | 8,441,787 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $101.41 |
52-Week Low | $0.48 | $85.06 |
Typical Hold Time | 16 Days | 41 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
IEFA (iShares Core MSCI EAFE ETF) trades at $96.20, down 1.08% with a bearish technical signal. The ETF manages $196 billion in assets, focusing on developed markets outside North America. Recent comparisons highlight its higher dividend yield versus competitors but lower recent performance than some peers. Technical indicators show oversold conditions with RSI at 28.63, while moving averages remain bearish with key support at $95.
The outlook remains cautious given bearish technical momentum and competitive pressure from lower-cost alternatives. International diversification benefits are offset by underperformance relative to global and emerging market ETFs. Key risks include currency fluctuations and concentrated U.S. market exposure driving defensive shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
